Company Filing History:
Years Active: 2001-2007
Title: Masako Tajima: Innovator in Cancer Research
Introduction
Masako Tajima is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of cancer research, particularly in understanding the mechanisms of stomach cancer. With a total of 3 patents, her work focuses on developing innovative diagnostic and therapeutic solutions for cancer patients.
Latest Patents
Tajima's latest patents include the establishment of an EBV-infected stomach cancer cell line. This invention involves an EBV strain that infects epithelial cells and a stomach cancer cell line that has been cancerated by EBV. The goal is to clarify the mechanism of how epithelial cells transform into stomach cancer due to EBV. Additionally, her research aims to develop a chemotherapeutic agent specifically for stomach cancer associated with EBV. The GTC-4 cell line, which was established through the culture of stomach cancer tissues, produces the EBV strain that infects epithelial cells and simultaneously generates EBV-related antigens in the supernatant. This advancement is crucial for developing a diagnostic drug for stomach cancer linked to EBV.
Career Highlights
Masako Tajima is currently employed at Eisai Company, Limited, where she continues her groundbreaking research. Her work has garnered attention in the scientific community, contributing to advancements in cancer treatment and diagnostics.
Collaborations
Tajima collaborates with esteemed colleagues, including Masakatsu Takanashi and Yukihisa Miyazawa. These partnerships enhance her research efforts and foster innovation in the field of cancer research.
Conclusion
Masako Tajima's contributions to cancer research, particularly through her innovative patents, highlight her role as a leading inventor in the field. Her work not only advances scientific understanding but also holds the potential to improve treatment options for stomach cancer patients.